Transthyretin amyloid cardiomyopathy (attr-CM)
Clinical trials for Transthyretin amyloid cardiomyopathy (attr-CM) explained in plain language.
Never miss a new study
Get alerted when new Transthyretin amyloid cardiomyopathy (attr-CM) trials appear
Sign up with your email to follow new studies for Transthyretin amyloid cardiomyopathy (attr-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new infusion slow a heart disease caused by protein clumps?
Disease control Not yet recruitingThis study tests the long-term safety and effectiveness of an experimental drug called ALXN2220 in adults with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart and impair its function. Participants who completed an earlier …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase 3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a smartphone app keep heart patients out of the hospital? new study aims to find out.
Knowledge-focused Not yet recruitingThis study looks at whether a digital tool called Luscii is practical and acceptable for people with a rare heart condition called ATTR-CM. About 60 adults in Austria, Germany, and Italy will use a smartphone app and home devices to share health information with their care team. …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC